Clover Biopharmaceuticals, Ltd. (2197.HK)
HKD 0.26
(0.0%)
HKD 0.26
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -401.41 Million CNY | 67.96% |
| 2022 | -1.25 Billion CNY | 53.58% |
| 2021 | -2.69 Billion CNY | -446.59% |
| 2020 | -493.86 Million CNY | -262.5% |
| 2019 | -136.23 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -245.82 Million CNY | 38.76% |
| 2024 Q2 | -245.82 Million CNY | 7.38% |
| 2023 Q4 | -401.41 Million CNY | 4.41% |
| 2023 FY | -401.41 Million CNY | 67.96% |
| 2023 Q3 | -419.94 Million CNY | 48.06% |
| 2023 Q2 | -808.51 Million CNY | 2.86% |
| 2023 Q1 | -832.35 Million CNY | 33.57% |
| 2022 Q2 | -2.17 Billion CNY | 1.19% |
| 2022 Q1 | -2.2 Billion CNY | 18.45% |
| 2022 FY | -1.25 Billion CNY | 53.58% |
| 2022 Q4 | -1.25 Billion CNY | 1.85% |
| 2022 Q3 | -1.27 Billion CNY | 41.32% |
| 2021 FY | -2.69 Billion CNY | -446.59% |
| 2021 Q1 | -1.79 Billion CNY | 0.0% |
| 2021 Q3 | -2.72 Billion CNY | 0.0% |
| 2021 Q4 | -2.69 Billion CNY | 0.79% |
| 2020 FY | -493.86 Million CNY | -262.5% |
| 2019 FY | -136.23 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | -76.36 Million HKD | -425.623% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.26 Billion HKD | 107.622% |